ArticleJournal of nanobiotechnology2026
The exosomal miRNA/FOXN3 axis empowers fibroblasts with tumor-promoting functions via enhanced migration and altered secretome.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Malignant tumor tissues with high proliferative activity are frequently characterized by a rich abundance of cancer-associated fibroblasts (CAFs). Nevertheless, the precise molecular mechanisms by which CAF-tumor cell crosstalk drives malignant proliferation remain incompletely elucidated. In this study, we demonstrate that exosomal microRNAs derived from lung adenocarcinoma cells reprogram adjacent normal fibroblasts into CAFs through downregulation of their common target, FOXN3. Suppression of this transcriptional repressor enhances the expression of genes associated with cell migration and extracellular matrix remodeling, thereby potentiating CAF infiltration into the tumor core. The consequent spatial proximity between CAFs and tumor cells enables the aberrantly altered secretome of CAFs to exert robust paracrine effects on malignancy. By focusing on receptors that interact with these dysregulated secreted proteins, we evaluated the drug sensitivity of patients bearing highly proliferative tumors to receptor-targeting agents, revealing potential therapeutic opportunities. Collectively, our work offers a detailed molecular dissection of tumor cell proliferation and proposes translationally relevant strategies for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.